NEW YORK (GenomeWeb) – Paradigm today announced a partnership to provide its PCDx next-generation sequencing-based cancer diagnostic test to Translational Drug Development's (TD2) affiliated oncology provider networks.
The deal will provide oncologists in TD2's networks access to Paradigm's test in order to make tailored treatment decisions for patients.
According to Paradigm CEO Robert Penny, "PCDx is one of the most comprehensive, yet targeted, clinical-grade NGS-based tests on the market today." The test identifies changes to the genomic and proteomic profiles of a tumor and runs on the Thermo Fisher Scientific Ion Torrent Personal Genome Machine. "Our team's ability to interrogate the most relevant genomic targets at over 5,000x average depth of coverage with 66 therapeutic associations in [four to five] business days ensures the highest degree of quality and clinical relevance for patients and physician colleagues," he said.
Ann Arbor, Mich.-based Paradigm is a non-profit diagnostics firm spun out of the University of Michigan. In August 2014 the firm signed a partnership with Forma Therapeutics to evaluate molecular biomarkers.